Unlearn

Executive Summary

Unlearn is a San Francisco-based biotechnology company pioneering the use of artificial intelligence to create digital twins of clinical trial participants. Founded in 2017, the company's platform generates AI-driven forecasts that act as sophisticated external comparators, enabling biopharma sponsors to design and analyze clinical trials more efficiently. By reducing trial size and duration, Unlearn aims to accelerate drug development while maintaining decision confidence. The company is currently in Phase 1/2 development and has raised significant capital to advance its technology. With the growing demand for more efficient clinical trials, Unlearn's approach could substantially lower costs and time-to-market for new therapies.

Upcoming Catalysts (preview)

• Q3 2026Publication of Phase 2 trial results using digital twin comparator65% success
• Q3 2026Strategic partnership with major pharmaceutical company50% success
• Q3 2026Series C funding round closing80% success